PROXY STATEMENT

Company

Cadrenal Therapeutics, Inc.

Filed

June 11, 2024

Period of Report

July 29, 2024

Accession Number

0001213900-24-051803

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →